Daiichi Sankyo received Japanese marketing approval for its generic fentanyl citrate tape in dosages of 1, 2, 4, 6 and 8 mg on 15 February 2018. The product was listed in the NHI (National Health Insurance) reimbursement price list in Japan on 15 June 2018.

The tape is a once-daily transdermal opioid analgesic for treatment of moderate to severe cancer pain. Hitsamitsu Pharmaceutical developed the originator product, Fentos Tape, in order to provide stable pain control for cancer patients and received approval for the product back in 2010.

Manufacturing of generic fentanyl citrate tape will be carried out by Kyukyu Pharmaceutical and Daiichi Sankyo will market and promote the product.

Daiichi Sankyo said that it ‘expects that the release of the tape will help to expand its product line up of opioid analgesics and will offer a novel treatment option to patients suffering from cancer pain and healthcare providers in Japan, thus contributing to advances in medicine’.

Related articles
FDA approves first Suboxone generics for opioid dependence

EC accuses J&J and Novartis of delaying generic fentanyl

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.